These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Broad Applicability of Nivolumab in Melanoma Regardless of BRAF Mutation Status. Gangadhar TC; Schuchter LM JAMA Oncol; 2015 Jul; 1(4):427-8. PubMed ID: 26181246 [No Abstract] [Full Text] [Related]
4. Release the hounds! Activating the T-cell response to cancer. Sznol M; Longo DL N Engl J Med; 2015 Jan; 372(4):374-5. PubMed ID: 25482238 [No Abstract] [Full Text] [Related]
5. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials. Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250 [TBL] [Abstract][Full Text] [Related]
7. Skin cancer: less is as good as more in refractory melanoma. Hutchinson L Nat Rev Clin Oncol; 2014 Sep; 11(9):502. PubMed ID: 25091612 [No Abstract] [Full Text] [Related]
8. Strides in melanoma announced: maximizing value comes next. Tuma RS J Natl Cancer Inst; 2011 Jul; 103(13):997-9. PubMed ID: 21693727 [No Abstract] [Full Text] [Related]
9. Pembrolizumab for metastatic melanoma in a renal allograft recipient with subsequent graft rejection and treatment response failure: a case report. Kwatra V; Karanth NV; Priyadarshana K; Charakidis M J Med Case Rep; 2017 Mar; 11(1):73. PubMed ID: 28315636 [TBL] [Abstract][Full Text] [Related]
10. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Mahoney KM; Freeman GJ; McDermott DF Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918 [TBL] [Abstract][Full Text] [Related]
11. Melanoma: understanding relevant molecular pathways as well as available and emerging therapies. McKibbin T Am J Manag Care; 2015 Sep; 21(10 Suppl):S224-33. PubMed ID: 26619296 [TBL] [Abstract][Full Text] [Related]
13. Aflibercept, ipilimumab, and vemurafenib. Hussar DA; Au AY J Am Pharm Assoc (2003); 2012; 52(2):291-4. PubMed ID: 22370387 [No Abstract] [Full Text] [Related]
14. Does adjuvant therapy for high-risk melanoma with either immunotherapy or targeted therapy affect therapeutic choices at relapse? Postow MA Clin Adv Hematol Oncol; 2018 May; 16(5):353-355. PubMed ID: 29851931 [No Abstract] [Full Text] [Related]
15. Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma. Lim SY; Menzies AM; Rizos H Cancer; 2017 Jun; 123(S11):2118-2129. PubMed ID: 28543695 [TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint inhibitors and targeted therapies for metastatic melanoma: A network meta-analysis. Pasquali S; Chiarion-Sileni V; Rossi CR; Mocellin S Cancer Treat Rev; 2017 Mar; 54():34-42. PubMed ID: 28189914 [TBL] [Abstract][Full Text] [Related]
17. Vemurafenib in melanoma with BRAF V600E mutation. Lott JP N Engl J Med; 2011 Oct; 365(15):1449-50; author reply 1450. PubMed ID: 21995400 [No Abstract] [Full Text] [Related]
18. Vemurafenib in melanoma with BRAF V600E mutation. Dalle S; Poulalhon N; Thomas L N Engl J Med; 2011 Oct; 365(15):1448-9; author reply 1450. PubMed ID: 21995399 [No Abstract] [Full Text] [Related]
19. Vemurafenib in melanoma with BRAF V600E mutation. Morita H; Nagai R N Engl J Med; 2011 Oct; 365(15):1448; author reply 1450. PubMed ID: 21995398 [No Abstract] [Full Text] [Related]
20. Rare heart risk found with checkpoint inhibitors. Printz C Cancer; 2017 May; 123(9):1483-1484. PubMed ID: 28430361 [No Abstract] [Full Text] [Related] [Next] [New Search]